Oncology 2020: From Invention to Outcomes

Posted by Jon Roffman on Mar 12, 2020 8:03:05 AM

Pranav Srivastava co-wrote this blog post with Jon Roffman. 

In the last three years alone, the FDA has given the green light to nearly 50 new cancer drugs. Were excited to see what 2020 has in store for this sector, as biopharma companies continue to bring these novel therapies and diagnostics to market. The fast pace of innovation in the oncology market presents increasingly complex challenges to manufacturers seeking to maximize the benefit that they can deliver to patientsWe’re committed to helping our client partnerand their customers thrive and ultimately improve outcomes for cancer patientsWith that in mind, our oncology practice is focused on three core dimensions that will be central to oncology manufacturers in the year ahead: navigating clinical pathways that drive the majority of treatment decisions in oncology; leveraging AI to deliver more relevant and valuable information to customers at the point of care; and delivering solutions that help customers better support their patients.


>
Read More

Powering Up Your Oncology Patient Support Program

Posted by Rachael Pius on Nov 20, 2019 8:00:00 AM

Gila Allswang co-wrote this blog post with Rachael Pius.

As oncology patients and caregivers continue to play a more active role in their healthcare decisions and have more options available to them than ever before, many pharma companies are upping their investment in patient support programs. While patient-centered care can empower and engage patients by building their knowledge—and can often drive competitive differentiation—it’s also fraught with its own challenge: Oncology patients simply are not aware of the service offerings provided by manufacturers and are much less likely to use them. On average, only 46% of oncology patients and caregivers are aware of the offerings available to them, according to ZS’s recent survey on patient support programs. In many cases they may also find the offerings from other stakeholders in the health ecosystem to be more relevant to meet their needs. Further, oncology patients are offered support from many different players across the healthcare ecosystem—patient advocacy, specialty pharmacy, payers, hospital systems and pharmaceutical manufacturers are all offering patients support. There’s a high degree of overlap across the landscape, so it’s important for manufacturers to understand where patients are accessing support and why.


>
Read More

Using the ‘Goldilocks Principle’ to Develop Data-Driven Oncology Account Strategies

Posted by Anshul Agarwal on Jan 15, 2019 8:00:00 AM

Scott Sandford and Abhishek Singh co-wrote this blog post with Anshul Agarwal.

The “Goldilocks principle,” which borrows its concept from the famous children’s story to describe when something is “just right,” can be applied to many situations, and the oncology landscape is no exception. Given the evolution of pharmaceutical manufacturer strategies in approaching oncology accounts and the data needed to support these strategies, manufacturers need to know what’s “just right” when it comes determining the resources needed for each account—a lesson that they can learn from Ms. Goldilocks and her friends, the bears.


>
Read More

Behind the Consultant Curtain: Leveraging Your Segment’s Strengths

Posted by Malik Kaman on Jan 8, 2018 8:00:00 AM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part two in a two-part series.

In our previous post, we discussed the four typical “segments” of oncology companies:

  1. Original Innovators: High prior oncology success, low commercial sophistication
  2. The Space Invaders: Low prior oncology success, high commercial sophistication
  3. The New Kids on the Block: Low prior oncology success, low commercial sophistication
  4. The Vanguard: High prior oncology success, high commercial sophistication

>
Read More

Going Beyond the Buzz of CAR-T Therapy

Posted by Robert Rovner on Dec 21, 2017 10:21:09 AM

There’s no doubt that chimeric antigen receptor T-cell (CAR-T) therapies have been generating increased interest over the past four years at the American Society of Hematology’s (ASH) Annual Meeting. In 2014, 34 abstracts on CAR-T therapies were presented at ASH, a number that more than tripled to 110 abstracts by 2016. This year, more than 140 CAR-T abstracts were presented to a packed Georgia World Congress Center in Atlanta. While some questions about this novel approach to cancer treatment remain unanswered, one thing is for certain: CAR-T therapies are here to stay. 


>
Read More